FIC20230030I1 - mirikitsumabi - Google Patents

mirikitsumabi

Info

Publication number
FIC20230030I1
FIC20230030I1 FIC20230030C FIC20230030C FIC20230030I1 FI C20230030 I1 FIC20230030 I1 FI C20230030I1 FI C20230030 C FIC20230030 C FI C20230030C FI C20230030 C FIC20230030 C FI C20230030C FI C20230030 I1 FIC20230030 I1 FI C20230030I1
Authority
FI
Finland
Prior art keywords
mirikizumab
Prior art date
Application number
FIC20230030C
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FIC20230030I1 publication Critical patent/FIC20230030I1/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FIC20230030C 2013-03-08 2023-10-03 mirikitsumabi FIC20230030I1 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361774732P 2013-03-08 2013-03-08
PCT/US2014/020064 WO2014137962A1 (en) 2013-03-08 2014-03-04 Antibodies that bind il-23

Publications (1)

Publication Number Publication Date
FIC20230030I1 true FIC20230030I1 (fi) 2023-10-03

Family

ID=51488096

Family Applications (1)

Application Number Title Priority Date Filing Date
FIC20230030C FIC20230030I1 (fi) 2013-03-08 2023-10-03 mirikitsumabi

Country Status (40)

Country Link
US (3) US9023358B2 (fi)
EP (3) EP4311558A3 (fi)
JP (1) JP6096938B2 (fi)
KR (2) KR20170103037A (fi)
CN (1) CN105307681B (fi)
AP (1) AP2015008708A0 (fi)
AR (1) AR094877A1 (fi)
AU (1) AU2014226094B2 (fi)
BR (1) BR112015019611B1 (fi)
CA (1) CA2901462C (fi)
CL (1) CL2015002388A1 (fi)
CY (2) CY1123589T1 (fi)
DK (1) DK2964258T3 (fi)
EA (1) EA031524B1 (fi)
EC (1) ECSP15038626A (fi)
ES (1) ES2822662T3 (fi)
FI (1) FIC20230030I1 (fi)
FR (1) FR23C1036I1 (fi)
HK (1) HK1212252A1 (fi)
HR (1) HRP20201633T1 (fi)
HU (2) HUE051357T2 (fi)
IL (2) IL240731B (fi)
JO (1) JOP20140049B1 (fi)
LT (1) LT2964258T (fi)
MA (1) MA38382A1 (fi)
MX (1) MX370396B (fi)
MY (1) MY171226A (fi)
NL (1) NL301247I2 (fi)
PE (1) PE20151529A1 (fi)
PH (1) PH12015501994A1 (fi)
PL (1) PL2964258T3 (fi)
PT (1) PT2964258T (fi)
RS (1) RS60928B1 (fi)
SG (1) SG11201507176VA (fi)
SI (1) SI2964258T1 (fi)
TN (1) TN2015000348A1 (fi)
TW (1) TWI636063B (fi)
UA (1) UA123198C2 (fi)
WO (1) WO2014137962A1 (fi)
ZA (1) ZA201505285B (fi)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
EA201890741A1 (ru) * 2015-10-30 2018-10-31 Эли Лилли Энд Компани Биспецифические антитела против cgrp/il-23 и их применения
AR111845A1 (es) 2017-05-03 2019-08-28 Lilly Co Eli Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos
TWI744617B (zh) 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
TWI725532B (zh) 2018-09-11 2021-04-21 美商美國禮來大藥廠 治療牛皮癬之方法
TW202103734A (zh) 2019-04-22 2021-02-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
JP2022552323A (ja) 2019-10-15 2022-12-15 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ/エステラーゼ欠損哺乳動物細胞株
JP2023509373A (ja) 2019-12-20 2023-03-08 ノヴァロック バイオセラピューティクス, リミテッド 抗インターロイキン-23 p19抗体およびそれの使用方法
CN111718414B (zh) * 2020-06-12 2021-03-02 江苏荃信生物医药有限公司 抗人白介素23单克隆抗体及其应用
WO2022041390A1 (zh) * 2020-08-28 2022-03-03 江苏荃信生物医药股份有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法
TW202224702A (zh) 2020-09-10 2022-07-01 美商美國禮來大藥廠 治療性抗體調配物
WO2022251623A1 (en) 2021-05-28 2022-12-01 Eli Lilly And Company Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
CN113698480B (zh) * 2021-09-18 2022-07-01 东大生物技术(苏州)有限公司 一组il-23单克隆抗体及其医药用途
WO2023056417A1 (en) 2021-09-30 2023-04-06 Eli Lilly And Company Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
WO2024077113A1 (en) 2022-10-06 2024-04-11 Eli Lilly And Company Methods of treating fatigue in ulcerative colitis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
MXPA05009717A (es) 2003-03-10 2005-10-18 Schering Corp Usos de agonistas y antagonistas de interleucina-23; reactivos relacionados.
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2007005955A2 (en) * 2005-06-30 2007-01-11 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
CN101248088A (zh) * 2005-08-25 2008-08-20 伊莱利利公司 抗il-23抗体
PT1937721E (pt) * 2005-08-25 2010-09-17 Lilly Co Eli Anticorpos anti-il-23
JP5350793B2 (ja) 2005-08-31 2013-11-27 メルク・シャープ・アンド・ドーム・コーポレーション 改変抗il−23抗体
EA035459B1 (ru) * 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
CN103396489A (zh) * 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
ATE554791T1 (de) 2007-02-23 2012-05-15 Schering Corp Gentechnisch hergestellte anti-il-23p19- antikörper
DK2131860T3 (da) * 2007-03-20 2014-01-13 Lilly Co Eli Anti-sclerostin-antistoffer
CA2683568A1 (en) * 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US20120264917A1 (en) * 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
BR112013011065B1 (pt) * 2010-11-04 2022-03-15 Boehringer Ingelheim International Gmbh Anticorpo anti-il-23p19 humanizado ou seu fragmento de ligação ao antígeno, seu uso e composição farmacêutica
CA2833212C (en) * 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides

Also Published As

Publication number Publication date
KR20150113202A (ko) 2015-10-07
KR20170103037A (ko) 2017-09-12
TWI636063B (zh) 2018-09-21
AP2015008708A0 (en) 2015-09-30
CN105307681A (zh) 2016-02-03
MX2015011959A (es) 2016-04-07
US20170275356A1 (en) 2017-09-28
NZ711147A (en) 2021-03-26
HUE051357T2 (hu) 2021-03-01
CY2023021I1 (el) 2024-02-16
EA031524B1 (ru) 2019-01-31
AU2014226094A1 (en) 2015-08-27
SG11201507176VA (en) 2015-10-29
CY1123589T1 (el) 2022-03-24
AU2014226094B2 (en) 2016-06-23
NL301247I1 (nl) 2023-10-11
TW201520225A (zh) 2015-06-01
EP2964258A4 (en) 2016-10-12
IL240731B (en) 2020-01-30
WO2014137962A1 (en) 2014-09-12
UA123198C2 (uk) 2021-03-03
MY171226A (en) 2019-10-03
EP4311558A2 (en) 2024-01-31
IL240731A0 (en) 2015-10-29
MX370396B (es) 2019-12-11
RS60928B1 (sr) 2020-11-30
HUS2300036I1 (hu) 2023-11-28
TN2015000348A1 (en) 2017-01-03
ES2822662T3 (es) 2021-05-04
US9688753B2 (en) 2017-06-27
HRP20201633T1 (hr) 2020-12-25
CL2015002388A1 (es) 2016-03-04
US20140255422A1 (en) 2014-09-11
ZA201505285B (en) 2017-11-29
MA38382A1 (fr) 2017-11-30
BR112015019611B1 (pt) 2023-05-02
PT2964258T (pt) 2020-11-06
EP3789037A1 (en) 2021-03-10
IL272042A (en) 2020-02-27
CN105307681B (zh) 2018-06-26
EP4311558A3 (en) 2024-04-10
PE20151529A1 (es) 2015-10-28
FR23C1036I1 (fr) 2023-12-08
PL2964258T3 (pl) 2021-02-08
EP2964258B1 (en) 2020-09-02
EA201591368A1 (ru) 2015-12-30
HK1212252A1 (en) 2016-06-10
CA2901462C (en) 2017-07-25
CA2901462A1 (en) 2014-09-12
IL272042B (en) 2021-07-29
DK2964258T3 (da) 2020-09-14
KR101775115B1 (ko) 2017-09-05
BR112015019611A2 (pt) 2017-08-22
JOP20140049B1 (ar) 2021-08-17
EP2964258A1 (en) 2016-01-13
US20150232552A1 (en) 2015-08-20
SI2964258T1 (sl) 2020-10-30
JP6096938B2 (ja) 2017-03-15
ECSP15038626A (es) 2015-11-30
JP2016510744A (ja) 2016-04-11
NL301247I2 (nl) 2023-11-01
PH12015501994A1 (en) 2016-01-11
US9023358B2 (en) 2015-05-05
LT2964258T (lt) 2020-10-12
AR094877A1 (es) 2015-09-02

Similar Documents

Publication Publication Date Title
NL301247I2 (nl) mirikizumab
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
DK3077047T3 (da) Aramcholsalte
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T3 (da) Bindestrimler
DK3052081T3 (da) Pastil
DK2946640T3 (da) Langmuir-probe
DK3071227T3 (da) Fiskevaccine
DE102013106534B8 (de) Chromatographiepipettenspitze
DE112014001252A5 (de) Aufbissschiene
DK2981168T3 (da) Laminitiskile
DK3086679T3 (da) Sportssko
FI10343U1 (fi) Mittateippi
FI10138U1 (fi) Kelkkateltta
ES1078715Y (es) Mosquitera
DE112014005422A5 (de) Friktionsfalschdrallaggregat
BR112016000501A2 (pt) Nalador
FI10440U1 (fi) Monikäyttösuutin
FI10396U1 (fi) Tielana
FI20136332A (fi) Energiapuukoura
FI10399U1 (fi) Klapivaste
ES1093505Y (es) Aerociclo
ES1093455Y (es) Columbario